Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. It engages in the development of therapies initially for basal cell carcinoma nevus syndrome (BCCNS) cancers by utilizing itraconazole; development of therapies initially for basal cell carcinoma (BCC) cancers; and SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. The company was founded in 1992 and is based in Tampa, Florida.
Frequently asked questions
What sector does Inhibitor Therapeutics Inc (INTI) operate in?
Inhibitor Therapeutics Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Inhibitor Therapeutics Inc (INTI) current stock price?
As of the latest data, Inhibitor Therapeutics Inc stock price is $0.08, with a previous close of $0.06. Inhibitor Therapeutics Inc gained $0.02 in the last trading session, representing a 31.15% increase.
What is Inhibitor Therapeutics Inc (INTI) current market capitalization?
Inhibitor Therapeutics Inc market cap is approximately 13.98 million.
What is Inhibitor Therapeutics Inc (INTI) Earnings Per Share (EPS)?
The trailing EPS is -$0.02.
What is Inhibitor Therapeutics Inc (INTI) EBITDA?
Inhibitor Therapeutics Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -618.60 thousand.
Does Inhibitor Therapeutics Inc (INTI) pay dividends?
No. Inhibitor Therapeutics Inc does not pay a dividend.
What is Inhibitor Therapeutics Inc (INTI) beta (volatility) score?
Inhibitor Therapeutics Inc has a beta of -0.697, indicating lower volatility than the overall market.
